Published Date: 08 Mar 2023
At a trial in Georgia on Wednesday, three drug traffickers won a case brought by the family of a drug addict, accusing the company of selling drugs.
Read Full NewsFor men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.
Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.
Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.
1.
Nature Retracts Cancer Study Suggesting Treatment Is Better Earlier in the Day
2.
In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?
3.
Why Are These Bones and Teeth Where They Shouldn't Be?
4.
ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?
5.
Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.
1.
Machine Learning for Bone Marrow Ecosystem Analysis
2.
Patient Management for Bone Marrow Functional Reserve Maintenance
3.
Leukemia: Understanding the Disease and Its Impact on Patients
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation